EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Current Quarter	$-0.79	Next Quarter	$-0.81
Current Year	$-3.01	Next Year	$-1.35
QoQ Growth	-2.5%	YoY Growth	+55.1%
3Y EPS CAGR	-4.5%	Target Price	$36.27
Consensus	Buy	Upside	+158.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EYPT	$14.04	+3.46%	744.38K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EYPT	$14.04	+3.5%	744.38K
3
4
5
6

EYPT

EYPT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get EyePoint Pharmaceuticals Inc. Data in Excel

Get EyePoint Pharmaceuticals Inc. Data in Excel